Overall Survival (OS) Impact for NSCLC Patients with irAE and Non-irAE Hospital Admissions During First line Pembrolizumab Treatment
07:30am - 03:35pm EDT - April 5, 2024


Overall Survival (OS) Impact for NSCLC Patients with irAE and Non-irAE Hospital Admissions During First line Pembrolizumab Treatment icon

Abstract: JNCCN23-0529 https://jnccn.org/view/journal...


Author(s):
  • Adam Khorasanchi, MD, Hospitalist, The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute

Tags: Member Institution Clinical Oncology

Display Label Action
036 - General Poster Session Download Handout
AdamKhorasanchi_NCCN24_Poster.pdf Download Handout